Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masako Mishima

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Internal Medicine (Tokyo, Japan)|August 28, 2018
Accelerated Progression of Hepatocellular Carcinoma during Immunosuppressive Therapy with Abatacept for Rheumatoid ArthritisSatoshi Yoshiji, Ken Takahashi, Kenji Sawada, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 25, 2025
Acquisition Process and Clinical Relevance of dMMR-Associated Mutational Signatures in Hepatocellular CarcinomaMasayuki Ueno, Haruhiko Takeda, Atsushi Takai, et al.
Carcinogenesis|January 29, 2026
MSH2 Prevents Liver Tumorigenesis by Regulating Cell Cycle Checkpoints under Chronic InflammationShigeharu Nakano, Atsushi Takai, Eriko Iguchi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 16, 2019
Utility of ultrasound-guided liver tumor biopsy for next-generation sequencing-based clinical sequencingYuji Eso, Tadayuki Kou, Hiroki Nagai, et al.
The Journal of Pathology|September 27, 2024
TERT upregulation promotes cell proliferation via degradation of p21 and increases carcinogenic potentialMasako Mishima, Atsushi Takai, Haruhiko Takeda, et al.
Scientific Reports|April 30, 2022
Mutational spectrum of hepatitis C virus in patients with chronic hepatitis C determined by single molecule real-time sequencingFumiyasu Nakamura, Haruhiko Takeda, Yoshihide Ueda, et al.
Carcinogenesis|February 22, 2021
Oncogenic transcriptomic profile is sustained in the liver after the eradication of the hepatitis C virusHaruhiko Takeda, Atsushi Takai, Eriko Iguchi, et al.
Journal of Gastroenterology|September 17, 2024
CRAFITY score as a predictive marker for refractoriness to atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective studyMasayuki Ueno, Haruhiko Takeda, Atsushi Takai, et al.
Journal of Gastroenterology|October 21, 2024
Publisher Correction: CRAFITY score as a predictive marker for refractoriness to atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective studyMasayuki Ueno, Haruhiko Takeda, Atsushi Takai, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 13, 2025
Lenvatinib Versus Atezolizumab Plus Bevacizumab as First-Line Treatment for Advanced Hepatocellular Carcinoma With a CRAFITY Score of 2: A Multi-Center Retrospective StudyMasayuki Ueno, Haruhiko Takeda, Atsushi Takai, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Internal Medicine (Tokyo, Japan)|August 28, 2018
Accelerated Progression of Hepatocellular Carcinoma during Immunosuppressive Therapy with Abatacept for Rheumatoid ArthritisSatoshi Yoshiji, Ken Takahashi, Kenji Sawada, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 25, 2025
Acquisition Process and Clinical Relevance of dMMR-Associated Mutational Signatures in Hepatocellular CarcinomaMasayuki Ueno, Haruhiko Takeda, Atsushi Takai, et al.
Carcinogenesis|January 29, 2026
MSH2 Prevents Liver Tumorigenesis by Regulating Cell Cycle Checkpoints under Chronic InflammationShigeharu Nakano, Atsushi Takai, Eriko Iguchi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 16, 2019
Utility of ultrasound-guided liver tumor biopsy for next-generation sequencing-based clinical sequencingYuji Eso, Tadayuki Kou, Hiroki Nagai, et al.
The Journal of Pathology|September 27, 2024
TERT upregulation promotes cell proliferation via degradation of p21 and increases carcinogenic potentialMasako Mishima, Atsushi Takai, Haruhiko Takeda, et al.
Scientific Reports|April 30, 2022
Mutational spectrum of hepatitis C virus in patients with chronic hepatitis C determined by single molecule real-time sequencingFumiyasu Nakamura, Haruhiko Takeda, Yoshihide Ueda, et al.
Carcinogenesis|February 22, 2021
Oncogenic transcriptomic profile is sustained in the liver after the eradication of the hepatitis C virusHaruhiko Takeda, Atsushi Takai, Eriko Iguchi, et al.
Journal of Gastroenterology|September 17, 2024
CRAFITY score as a predictive marker for refractoriness to atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective studyMasayuki Ueno, Haruhiko Takeda, Atsushi Takai, et al.
Journal of Gastroenterology|October 21, 2024
Publisher Correction: CRAFITY score as a predictive marker for refractoriness to atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective studyMasayuki Ueno, Haruhiko Takeda, Atsushi Takai, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 13, 2025
Lenvatinib Versus Atezolizumab Plus Bevacizumab as First-Line Treatment for Advanced Hepatocellular Carcinoma With a CRAFITY Score of 2: A Multi-Center Retrospective StudyMasayuki Ueno, Haruhiko Takeda, Atsushi Takai, et al.
Pageof 2